Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — IPO Roadshow (June 2024)
101 slides from Catheter Precision's IPO roadshow presentation, Jun 17, 2024
Slide 1: Catheter Precision NYSEAM: VTAK
Slide 2: Forward-Looking Statements and Estimates
Forward-Looking Statements and Estimates ‘This presentation and other materials referenced by this presentation contain or incorporate by reference “forward-looking statements” within the meaning of Sections 27A and 21E of the Securities Act of 1933 and Securities Exchange Act of 1934, respectively,
Slide 3: Free Writing Prospectus
Free Writing Prospectus This presentation highlights basic information about the Company and the offering. Because itis a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our Company. Except as o
Slide 4: Risk Factors
Risk Factors Investing in our securities involves a high degree of risk. You should carefully consider the risks described below, and those discussed under the section entitled "Risk Factors” contained in the Preliminary Prospectus, our 10-K Annual Report and our subsequent Quarterly Reports, togeth
Slide 5: Advancing care through meaningful innovation
((sreciion 7 y & Advancing care through meaningful innovation Design and manufacture innovative medical devices 222, _ intended to improve patient outcomes, reduce cost, and increase hospital productivity
Slide 6: Global Electrophysiology Market
Global Electrophysiology Market The EP market is projected to grow to $15.1 bn by 2028! Population growth, increasing rates of heart diseases and the rising cost of healthcare are driving growth in the electrophysiology and catheter ablation markets. The global electrophysiology market was estimated
Slide 7: Product Portfolio
Product Portfolio Non-invasive 3D imaging system that enables le physicians to identify the origin of ventricular Wo arrhythmias pre procedure ~ FDA Cleared and CE Marked View Into Ventricular Onset Full-scale commercial launch in 2023* cost-effective solution for access site closure with suture ret
Slide 8: Sales Strategy
Sales Strategy USA Direct Sales Team EU Sales Managers and reczicn
Slide 9: Company milestones
Company milestones Viner LockeT First Clinical OC ication vivo™ilFDA | | Start of EU multi- Uockiey FM Publication on LeeT Ea a clearance center regist ee vivo BISY | first-in-man cases Acquisition of vivo™ LockeT US launch and first publication Conclusion of - Corporate first multi-center pe laa Me
Slide 10: Upcoming milestones
Upcoming milestones Last patient follow up in EU Registry Completion of EU Registry Registry and Phase 2 LockeT Data Conclusion of oe elie 2 Locke? LockeT (( Catheter Precision a
Slide 11: VIVO
Vier Non-invasive 3D Mapping System (( Catheter Precision 1 4
Slide 12: Ventricular Ablation Market
Ventricular Ablation Market The Ventricular Ablation Market is Growing ta Faster than the Electrophysiology Market as a bd Whole o Tachycardia ablation is forecasted to grow at 14.5 % CAGR through 2032, a faster rate than the broader electrophysiology and catheter ablation markets.* o Over a ten-yea
Slide 13: Current Ventricular ablation outcomes
Current Ventricular ablation outcomes ~46% of Ventricular Tachycardia recurrence after a 1- year follow up! 50-75% Ventricular Tachycardia Ablation success rate in structural disease heart? Major Complications in 8-10 % of Ventricular Tachycardia ablation procedures? 3 to 6 hours Ventricular Ablatio
Slide 14: Product Overview
Product Overview Vive Enhance Procedural Efficiency for Ventricular Arrhythmias in with Patient Specific Solutions Non-invasive 3D imaging system + Provides a 3D matrix model of the heart on a computer monitor with a superimposed activation map + Enables physicians to accurately target the anatomica
Slide 15: Product Overview
Product Overview p" > 4 « the _ \ i 4 | a / Si “a, Z * — xe a ei (aeezis5 (SS s, 5
Slide 16: Product Overview
Product Overview Capital Consumables aa § Laptop PC, VIVO™ software, 3D camera, Vectraplex Positioning patches Universal ECG cables, and software $31,250 or Free to the hospital with consumables bundle $2,000 per patient (( Cetheter Precision ie
Slide 17: VIVO - The Future of Ventricular Ablations
VIVO™ - The Future of Ventricular Ablations Maximize Efficiency ©) 27% shorter procedure time Precise Ventricular Insight @ 99.5%" accurate in ventricular onset localization Patient Specific Inputs Localize multiple arrhythmias morphologies pre or intra-procedure Streamline Workflow Determine potent
Slide 18: VIVO - The Future of Ventricular Ablations
VIVO™ - The Future of Ventricular Ablations Increases the efficacy of ventricular ablation procedures, particularly epicardial Reduces potential complications by arrhythmic substrates, whereby reducing procedure time? » ~ reducing the redo ablation raves Expands the number of VT ablation procedures
Slide 19: Ventricular arrhythmia procedural growth
VTAK believes that procedural growth over the next ten years will be focused on ablations for ventricular arrhythmias, with a virtually untapped market greater than the atrial fib market. (section
Slide 20: LockeT
LockeT Suture Retention Device A cost-effective solution for access site closure with suture retention, ensuring efficient hemostasis while prioritizing patient comfort. LockeT Demonstration Video
Slide 21: Product Overview
Product Overview The device is placed at the end of the procedure, allowing for hemostasis to occur at the access site. In the Lab Step 1: Create a standard figure : Step 2: Tighten and Step 3: Apply pressure of eight and remove sheaths. place sutures in LockeT. and rotate the handle 90°. Clean site
Slide 22: Product Overview
Product Overview In Recovery: Ls Step 4: Observe hemostasis. Step 5: When ready to discharge, unlock —_—_Step 6: Cut the sutures and remove Follow regular protocol. the LockeT by releasing the handle. from the access site. (( Cetheter Precision .
Slide 23: Meters
Meters
Slide 24: Addressable market
Addressable market Vascular Closure Devices Market was valued at USD $1.9 bn in 2023 and is poised to grow at an 8.4% CAGR from 2024 to 2030! | | Ps endusers | Applications Procedure Types o Hospitals o Interventional o Ambulatory o Diagnostic Cardiology Surgical Centers interventions o Electrophysi
Slide 25: LockeT
LockeT Suture Retention Device Katapadi et al. (2024) ‘Feasibility, safety and efficacy of a novel external compression vascular closure device: The LockeT Study’. Benefits achieved for median patient. 98% hemostasis at 2 hours after removal of the device 25
Slide 26: Competitive landscape
Competitive landscape Manual ; Stopcock Vascade MVP Perclose ProGlide Compression z HAEMONETICS' s > ] Rapid Hemostasis x Vv Vv Early Ambulation wv WwW v Vv ‘Small & Large Bore Vw Cost effective wv o (( Cetheter Precision ms
Slide 27: Cost effective
Cost effective Allows reduced number of devices per access site Meters
Slide 28: Near Term Goals
Near Term Goals ( EndofQ3 \/ Endofa4 2024 2024 Vive 5 New accounts 5 New accounts 2 Ongoing Ongoing evaluations evaluations 10 New accounts 20 New accounts 20 Ongoing 1 0 Ongoing evaluations evaluations $150,000/rep (ARR) || $290,000/rep (ARR) $1.8M (ARR) $4.1M (ARR)
Slide 29: Successful track record of CEO David Jenkins
Successful track record of CEO David Jenkins 4" —__ Arrhythmia: The Leading Edge in Cardiac Rhihm Menogemen! Transaetranin lat CEO & Chairman Founder & CEO Founder & President + + + Electrophysiology Electrophysiology Implantable device Focused Focused for obesity > > > Product CardioLab Sold to Sol
Slide 30: Strong Board governance and a purpose-driven team
Strong Board governance and a purpose-driven team Management David Jenkins — Chief Executive Officer 30+ years in the industry Former CEO & Chairman: Arrhythmia Research Technology, Inc., and EP MedSystems. Former founder & President of Transneuronix Margrit Tomassen — Interim Chief Financial Office
Slide 31: Capitalization
Capitalization Capitalization Common Stock Equivalents Common Stock 7,573,403 Series A Convertible Preferred 2,313,956 Series X Convertible Preferred! 12,656,011 Warrants (WAEP $5.31)? 11,042,137 Options (WAEP $1.7589) 989,593 Total Fully Diluted 34,575,100 1. Does not contain any price reset or ant
Slide 32: Entering the commercial phase
As Catheter Precision is entering the commercial phase with a solid sales infrastructure in place, VTAK believes that VIVO™ and LockeT can have a transformative impact on hospitals and the industry and can lead to improved outcomes for both patients and facilities. Meters
Slide 33: Appendix A
Appendix A Description of embedded animation Slide 15 of the Presentation includes an embedded animation, without audio, that illustrates how VIVO works through a simulation of the user interface, including a 3D model of a patient, the patient’s heart, an EKG, and a user panel. Set forth below are r
Slide 34: The new standard for patient specific planning of ventricular ablations
The new standard for patient specific e f, planning of ventricular ablations Say fe f we |
Slide 35: VIVO
Vive — Rightvs. (Fates
Slide 36: Slide 36
Slide 37: Slide 37
Slide 38: Slide 38
Slide 39: Slide 39
Slide 40: Mor.
Mor. )
Slide 41: Slide 41
Slide 42: Slide 42
Slide 43: (QESEIES,
(QESEIES,
Slide 44: Slide 44
Slide 45: Slide 45
Slide 46: Slide 46
Slide 47: Slide 47
Slide 48: —— tt EE
—— tt EE
Slide 49: Slide 49
Slide 50: Slide 50
Slide 51: —— ne
—— 8 ne
Slide 52: Slide 52
Slide 53: renee “FEF
renee “FEF
Slide 54: Slide 54
Slide 55: Slide 55
Slide 56: Slide 56
Slide 57: Slide 57
Slide 58: Slide 58
Slide 59: Slide 59
Slide 60: Slide 60
Slide 61: Slide 61
Slide 62: (Sea
(Sea
Slide 63: i] i (or.
i] i (or.
Slide 64: Slide 64
Slide 65: Slide 65
Slide 66: Nor.
Nor. esas SRT ato. teen
Slide 67: Slide 67
Slide 68: Slide 68
Slide 69: Slide 69
Slide 70: Slide 70
Slide 71: Slide 71
Slide 72: Slide 72
Slide 73: ue
ue
Slide 74: Slide 74
Slide 75: Slide 75
Slide 76: Appendix B
Appendix B Hyperlinked LockeT Demonstration Video (Slide 20) A hyperlink is provided to an animated video which illustrates the functioning and use of LockeT, hosted on the YouTube platform at www.youtube.com/watch?v=SUQZbqAnGhQ. A transcript of the video follows representative graphic images from t
Slide 77: LockeT
LockeT Intuitive suture retention device Mesecinisn, Music A
Slide 78: Slide 78
Slide 79: Slide 79
Slide 80: Quick hemostasis
Quick hemostasis
Slide 81: Threaded with ease
Threaded with ease
Slide 82: Po © one op eoGoOn
Po © one op eoGoOn
Slide 83: Slide 83
Slide 84: Transcript
Transcript 0:00 [Music] 0:04 Achieving hemostasis following large 0:07 bore femoral vein access remains a 0:11 challenge. Catheter Precision's LockeT 0:14 suture retention device features a 0:16 simple design, offering an easy to use, 0:18 comfortable and cost-effective solution 0:20 for hemostasis
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Slide 89: Slide 89
Slide 90: Slide 90
Slide 91: Slide 91
Slide 92: Slide 92
Slide 93: Slide 93
Slide 94: Slide 94
Slide 95: Slide 95
Slide 96: Slide 96
Slide 97: Slide 97
Slide 98: +
+
Slide 99: Slide 99
Slide 100: Slide 100
Slide 101: Slide 101